- Home
- KALV vs DPG Comparison
KALV vs DPG Comparison
Compare KALV & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KALV | DPG |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 464.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KALV | DPG |
|---|---|---|
| Price | $15.53 | $12.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $27.17 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 150.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,426,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $204.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.30 | $7.90 |
| 52 Week High | $17.30 | $13.58 |
Technical Indicators
Market Signals| Indicator | KALV | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 53.76 |
| Support Level | $14.83 | $12.77 |
| Resistance Level | $16.30 | $12.95 |
| Average True Range (ATR) | 0.87 | 0.15 |
| MACD | -0.20 | 0.03 |
| Stochastic Oscillator | 34.81 | 83.52 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.